Abstract
ABSTRACT Biopharmaceuticals have the potential to contribute immensely towards improving the health and quality of life of people. However, there is a gap in the availability of medical services in India and inequality in disseminating health benefits to the poor. Several issues are associated with biopharmaceuticals, such as increasing cost of treatments, access, affordability, safety, efficacy, quality, and intellectual property rights. Hence, the present paper addresses the crucial questions on the emerging challenges in the Indian biopharmaceutical industry regarding the patent cliff and biosimilars. What are the technological and institutional challenges faced by the biosimilars producing firms? Whether biosimilars could meet the regulatory requirements of safety, efficacy, and whether they will meet global regulatory standards? This article further analyses the regulatory pathways for commercial approval of biosimilars.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
